Search
Oral Presentation
Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Koshkin V, Barthélémy P, Gravis G, et al.
Oral Presentation
Safety and antitumor activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 Insertion (ex20ins) mutations who received prior Amivantamab
Passaro A, Yu H, Nguyen D, et al.
Oral Presentation
Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: primary analysis of the randomized phase II NIBIT-ML1 study
Giacomo A, Simonetti E, CalabroD L, et al.
Poster Presentation
Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Tabernero J, Taieb J, Fakih M, et al.